我們已在上線！進一步了解

Icon

ICLR

市值 US$131億

170.18 USD

-4.95

2.83%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

170.18

0.00

0%

1天

-2.83%

5天

3.05%

1個月

-2.16%

3個月

0.11%

6個月

47.24%

今年迄今

-9.8%

1年

-9.7%

5年

-38.47%

10年

120.16%

關於： Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.

員工： 40,100

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 31.3%

中性 56.3%

負面 12.5%

ICON Schedules Third Quarter 2026 Earnings Conference Call

DUBLIN--(BUSINESS WIRE)--ICON Schedules Third Quarter 2026 Earnings Conference Call.

ICON Schedules Third Quarter 2026 Earnings Conference Call

Zacks Investment Research

Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?

Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?

Oakmark Concentrated Strategy Q2 2026 Performance Review

The portfolio's return was 9.21% (net) for the reporting period. Centene, ICON and Keurig Dr Pepper were the contributors during the quarter. Intercontinental Exchange, Salesforce and ConocoPhillips were the detractors during the quarter.

Oakmark Concentrated Strategy Q2 2026 Performance Review

Zacks Investment Research

Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?

ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.

Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?

Zacks Investment Research

ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen

ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.

ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen

ICON Announces Private Offering of Notes

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”), intends to offer one or more series of senior notes (the “Notes”), in a private offering (the “Offering”) with registration rights, subject to market and other conditions. The Notes will be guaranteed on a senior unsecured basis by ICON.

ICON Announces Private Offering of Notes

ICON Announces Results of Annual General Meeting

DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.

ICON Announces Results of Annual General Meeting

ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcript

ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcript

ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcript

Icon Q2 Earnings Call Highlights

Icon NASDAQ: ICLR reported second-quarter 2026 revenue growth and strong bookings as higher pass-through activity supported the top line, while the company continued to manage business-mix pressures affecting reported margins.

Icon Q2 Earnings Call Highlights

Zacks Investment Research

Icon PLC (ICLR) Lags Q2 Earnings Estimates

Icon PLC (ICLR) came out with quarterly earnings of $2.56 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $3.26 per share a year ago.

Icon PLC (ICLR) Lags Q2 Earnings Estimates

查看新聞排名

價格圖表採用Lightweight Charts™實作